Samer A. Al'Hadidi, MD, MS

home / authors / samer-a-al-hadidi-md-ms

Hematologist/oncologist and assistant professor in the Department of Internal Medicine, Division of Hematology and Oncology at the University of Arkansas for Medical Sciences.

Articles

Considering 3-Year Follow-Up Data of Cilta-Cel in Multiple Myeloma

December 19th 2024

Samer A. Al’Hadidi, MD, discusses the follow-up data for ciltacabtagene autoleucel in patients with multiple myeloma.

Discussion of Real-World Myeloma Care Emphasizes Value of Personalized Medicine

Samer A. Al'Hadidi, MD, MS

December 6th 2024

Samer A. Al’Hadidi, MD, discusses the importance of personalized medicine in patients with multiple myeloma.

Functional High-Risk is a Leading Rationale for Early CAR T in Myeloma

Samer A. Al'Hadidi, MD, MS

November 26th 2024

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory multiple myeloma.

Quadruplets Seen as Top Option in Transplant-Ineligible Multiple Myeloma Due to Efficacy

Samer A. Al'Hadidi, MD, MS

November 8th 2024

Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with transplant-ineligible multiple myeloma.